Reverse Mergers in Biopharma

by | Jun 13, 2019

Reverse mergers have been a relatively quick method for companies to gain a public listing as an alternative to IPOs. A private company looking to go public merges with a company that is already publicly traded and changes the ticker symbol. Technically, the public company is acquiring the private company, hence the ‘reverse’ part. Also, it’s not uncommon to see public companies outside of the life sciences space on one side of the deal. Following a conversation over on Twitter (thanks, @syinvesting), we used the DealForma deals database to generate a quick list of 91 reverse mergers with biotechnology, medical device, and diagnostics companies since 2008.

Run your own analysis with your DealForma access.

Schedule a Demo to See it in Action

Biopharma Reverse Mergers since 2008

Companies with a public listing reverse merged with private biopharma. Stage represents the private biopharma at signing. Excludes leveraged buyouts (LBOs) where the acquirer is a financial firm.

Good so far?

You scrolled all the way here. Great! This quick list of deals can lead to some interesting analyses: stock price moves, stages of companies, therapeutic areas, technologies, and more. Contact us here or on Twitter @DealForma to chat about this.

Chris Dokomajilar is the Founder / CEO of DealForma and has been an industry analyst for over a decade. He analyzed the data and produced the table for this article. More about Chris.

Want data for your analysis? Want us to do it? Subscribers get both.

Schedule your demo of the DealForma database to see how we help you get better reports done faster.

16,326

Deal Profiles

8,389

Funding Rounds

18,249

Company Profiles

10,337

Product Profiles

119K+

Clinical Trials

3,397

Business Developers

Specifically for Biotech, Pharma, Device, and Diagnostics

More from the DealForma Blog

Biotech Companies in Major Industry Centers Rake in the Cash

Location, Location, Location: Real estate costs a lot in the three largest biotech hubs, but it’s a charm for raising capital. Biotech companies raised $37.4 billion globally in 1027 rounds of venture financing over the past four years from 2015 through the third quarter of 2018 and companies located in the San Francisco Bay Area, greater Boston area, and San Diego County accounted for 55 percent of the total raised and 46 percent of the financing activity.

You met at BIO. Now it's Deal Time.

With thousands of company profiles and a decade of deals specifically in biotech and pharma, you'll take the guesswork out of deal comps. Schedule your customized demo to see how DealForma helps you win that term sheet with better data.

DealForma is the biopharma database providing you comprehensive information and analyst support hours to help you be more confident using quality data in your business development research.

 

Company

About Us

Analysis / Blog

Contact Us

Product

Support

Pricing

Connect

Made in San Mateo, CA and around the world    support@dealforma.com   (650) 353-9363  Terms  Privacy

Copyright © 2019 DealForma

Share This